# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Barclays analyst Luke Sergott initiates coverage on Charles River (NYSE:CRL) with a Equal-Weight rating and announces Price ...
Argus Research analyst David Toung downgrades Charles River (NYSE:CRL) from Buy to Hold.
Lentiviral vector CDMO collaboration to support advanced cell therapies for hematological cancersCharles River Laboratories Int...
Project will utilize an integrated approach to develop an in vitro alternative to inhalation toxicology studiesCharles River La...
Mizuho analyst Ann Hynes initiates coverage on Charles River (NYSE:CRL) with a Neutral rating and announces Price Target of ...